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Purpose of the study
Use of protease inhibitors has been associated with
plasma lipids and glucose changes. Co-formulated lopi-
navir/ritonavir (LPV/r) is a potent antiretroviral drug.
However, it has been implicated in lipid and glucose
abnormalities. We evaluated changes in lipids and glucose
in HAART naïve and experienced patients enrolled in a
clinical trial of LPV/r-based regimen.
Methods
This prospective, 24-month, open label, phase IV, multi-
center study, comprised of 131 Greek HIV+ subjects rand-
omized into two groups according to PI and HAART
history. Group A (N = 91) included antiretroviral- or PI-
naïve subjects who initiated a LPV/r-based regimen, and
group B (N = 40) included PI-experienced subjects who
switched their regimen to include LPV/r. All subjects
underwent clinical and laboratory evaluation (total cho-
lesterol [TC], triglycerides [TG], LDL, HDL, ApoB, glu-
cose) at baseline and at 3, 6, 12, 18 and 24 months of
follow-up. Changes in laboratory parameters were com-
pared within and between the two groups using linear
mixed effects models.
Summary of results
Mean fasting glucose levels declined from baseline to 24
months value of 10.3 mg/dl (p = 0.002) in group B while
remaining unchanged in group A. TG and TC levels were
higher at baseline in group B compared to group A with
higher baseline levels associated with higher end values
for both groups. Both markers tended to increase during
follow up, but never reached toxicity limits as defined by
CTCAE v3.0. TG increased 0.1 log10 mg/dl (p < 0.001)
from baseline in group A with no change in group B.
CD4+ cell levels at baseline of 80–350 resulted in lower
TG levels. A mean increase of 36.1 mg/dl (p < 0.001) and
24.9 mg/dl (p = 0.004) for group A and B, respectively,
was observed for TC at 24 months. HDL showed a statis-
tically significant mean increase of 6.2 mg/dl (p = 0.001)
for group A and a 5.1 mg/dl indicative increase for group
B (p = 0.071). TC/HDL ratio remained below 5 through-
out the study. ApoB values showed a 31.3 mg/dl mean
increase (p < 0.05) in group A.
Conclusion
Minimal differences were observed in fasting glucose and
lipid profile between HAART naïve and experienced sub-
jects receiving LPV/r in a 2-year study period. The TC and
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TG increase observed never reached toxicity levels. TC/
HDL, an important predictor of cardiovascular event
occurrence, remained below the critical value 5 for the
whole period. Severity of condition as defined by the
baseline CD4+ count affects TG levels.Page 2 of 2
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